Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDCD1 | Q15116 | 1/20 | 0.81 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.81 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.62 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | PKM | P14618 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | DHODH | Q02127 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | BACE1 | P56817 | 1/20 | 0.58 |
| ▸ | MDM4 | O15151 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21446872 | 0.90 | PDCD1 (1.00) | PDCD1CD274SIRT2HDAC3HDAC1 | |
| SCHEMBL6720875 | 0.89 | MEN1 (0.73) | PDCD1CD274SIRT2MEN1PKM | |
| SCHEMBL15775304 | 0.88 | PDCD1 (0.74) | PDCD1CD274SIRT2HDAC3MAPK1 | |
| SCHEMBL23258276 | 0.88 | PDCD1 (0.74) | PDCD1CD274SIRT2HDAC3MAPK1 | |
| SCHEMBL14855807 | 0.88 | SIRT2 (0.78) | PDCD1CD274SIRT2MEN1PKM | |
| SCHEMBL28552726 | 0.86 | PDCD1 (0.63) | PDCD1CD274SIRT2HDAC3MAPK1 | |
| SCHEMBL11079536 | 0.86 | PDCD1 (0.72) | PDCD1CD274SIRT2MEN1KMT2A | |
| SCHEMBL14252955 | 0.86 | PDCD1 (0.72) | PDCD1CD274SIRT2HDAC1HDAC2 | |
| SCHEMBL11826793 | 0.86 | PDCD1 (0.72) | PDCD1CD274SIRT2MEN1KMT2A | |
| SCHEMBL30050669 | 0.85 | PDCD1 (0.61) | PDCD1CD274SIRT2HDAC3MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1928844-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | Amgen, Inc (US) | 2008-06-11 | — | — | EP | claimed |
| WO-2007022380-A2 | BIS-ARYL AMIDE COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2007-02-22 | — | — | WO | claimed |
| EP-3628374-B1 | BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2023-08-30 | — | — | EP | disclosed |
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | disclosed |
| EP-4008716-A1 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008717-A2 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008717-A2 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| EP-4008716-A1 | NOVEL INHIBITORS OF INSULIN-LIKE GROWTH FACTOR 2 MRNA BINDING PROTEINS | Martin-Luther-Universität Halle-Wittenberg (DE) | 2022-06-08 | — | — | EP | disclosed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX LLC (US) | 2021-01-21 | — | — | US | disclosed |
| CN-107324975-B | Direct hydroxylation or amination method of photocatalytic benzene and derivatives thereof | 中国科学院理化技术研究所 | 2020-11-24 | — | — | CN | disclosed |
| WO-2002022608-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022604-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022606-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022607-A1 | PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| WO-2002022602-A2 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2002-03-21 | — | — | WO | disclosed |
| EP-1165494-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2002-01-02 | — | — | EP | disclosed |
| US-6323202-B1 | BENZAMIDE SUBSTITUTES WITH KETONE COMPOUNDS AS ENZYME INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-11-27 | — | — | US | disclosed |
| WO-2000058270-A2 | HSV PRIMASE INHIBITORS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-10-05 | — | — | WO | disclosed |
| US-3998951-A | Substituted 2-arylquinazolines as fungicides | FMC CORPORATION (US) | 1976-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | PDCD1 1323/4885CD274 3165/4885SIRT2 351/4885 |
| US-20210017166-A1 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | ROCK2, ROCK1, RHOT2 | PDCD1 3197/4885CD274 4201/4885SIRT2 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.